BioAge Labs (BIOA) used the UBS Global Biopharma Conference 2026 on Monday, 16 November 2026, to outline a revised strategy for BGE-102, its oral NLRP3 inhibitor. The company is moving the drug away from a near-term cardiovascular outcomes path and toward ophthalmology, led by diabetic macular edema.
BioAge Chief Strategy Officer BJ Sullivan said the company is building around the biology of human aging to find targets for cardiometabolic disease.
The shift follows Novo Nordisk's ZEUS trial, which tested the IL-6 inhibitor ziltivekimab in atherosclerotic cardiovascular disease with chronic kidney disease and failed. BioAge said the result changed the outlook for large outcomes studies. Management said the outcome suggests IL-6 may sit too far downstream and that investor appetite for five-year, $500 million-plus trials has weakened. BioAge still believes upstream NLRP3 biology is relevant and said it may revisit cardiovascular disease if future evidence, including its ARTEMIS study in acute MI, supports that return.
The company reported Phase I results for BGE-102. At the 120 mg dose, the drug produced 98% trough IL-1β suppression and complete pathway inhibition over 24 hours. BioAge said a 60 mg dose showed concordant results over three weeks. It reported an 86% reduction in CRP, along with reductions in IL-6 and fibrinogen, and described tolerability as placebo-like across cohorts. Lumbar puncture data confirmed cerebrospinal fluid penetration, and the company said retinal exposure was high across clinical species, including non-human primates.
BioAge said it has a little over $350 million in cash and expects that to fund operations through 2029.
The company said QUELL-DME, a Phase II proof-of-concept trial, will compare monotherapy and VEGF plus BGE-102 against baseline. The primary endpoint is best-corrected visual acuity, and BioAge expects data in the second half of 2025. The company said the oral route could help patients delay injections. It is targeting two groups: watch-and-wait patients, whom BioAge said make up about 40% of the DME population, and VEGF-treated patients with incomplete disease control.
BioAge's QUELL-CV, a Phase II dose-ranging trial in obese people with elevated CRP, is also ongoing. BioAge expects data by the end of 2024.